Audit and Remuneration Committee Membership

 

TIDMLPX 
 
RNS Number : 2856W 
Lipoxen PLC 
24 July 2009 
 
+--------------------------------------+--------------------------------------+ 
| For immediate release                |                         24 July 2009 | 
+--------------------------------------+--------------------------------------+ 
 
 
Lipoxen plc 
('Lipoxen' or 'the Company') 
 
 
Audit and Remuneration Committee Membership 
 
 
Lipoxen plc (AIM: LPX), a bio-pharmaceutical company specialising in the 
development of high-value differentiated biologicals, vaccines and siRNA 
delivery, advises that in its Board meeting following its successful Annual 
General Meeting today, the Company has altered the membership of its Audit and 
Remuneration Committees. Committee membership is now as below. 
 
 
Audit Committee: 
 
 
Sir Brian Richards, Non-executive Director (Chairman) 
Firdaus Jal Dastoor, Non-executive Director 
M Scott Maguire, Chief Executive Officer 
 
 
Remuneration Committee: 
 
 
Sir Brian Richards, Non-executive Director (Chairman) 
Firdaus Jal Dastoor, Non-executive Director 
Colin William Hill, Chief Financial Officer 
 
 
- Ends - 
For further information please contact: 
 
 
+-------------------------------------------------+-------------------------+ 
| Lipoxen plc                                     |    [phone]  | 
+-------------------------------------------------+-------------------------+ 
| M. Scott Maguire, Chief Executive Officer       |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Singer Capital Markets (nominated adviser)      |     [phone] | 
+-------------------------------------------------+-------------------------+ 
| Jeff Keating / Claes Spång                      |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Noble & Company                                 |   [phone]  | 
+-------------------------------------------------+-------------------------+ 
| John Llewellyn-Lloyd / Sam Reynolds             |                         | 
+-------------------------------------------------+-------------------------+ 
|                                                 |                         | 
+-------------------------------------------------+-------------------------+ 
| Buchanan Communications                         |     [phone] | 
+-------------------------------------------------+-------------------------+ 
| Mary-Jane Elliott, Lisa Baderoon, Rebecca Skye  |                         | 
| Dietrich, Catherine Breen                       |                         | 
+-------------------------------------------------+-------------------------+ 
 
 
Notes for Editors 
 
 
About Lipoxen 
Lipoxen plc is a biopharmaceutical company focused on the development of new and 
improved biologic drugs and vaccines. Lipoxen has three proprietary patented 
technology platforms: 
 
 
1) PolyXen - for extending the efficacy and half life of biologic drugs 
2) ImuXen - for creating new vaccines and improving existing vaccines 
3) SiRNAblate - for the delivery of siRNA 
 
 
Lipoxen's technology is designed to improve the efficacy, safety, stability, 
biological half-life and immunologic characteristics of its products. 
 
 
Lipoxen has multiple drug and vaccine programmes in development. Two products 
are in clinical development, SuliXen, a long acting insulin and ErepoXen, a 
long-acting erythropoietin (EPO). Lipoxen's preclinical pipeline includes 
vaccines against HIV, influenza and malaria and Factor VIII through an exclusive 
license with Baxter, the global healthcare company. 
 
 
The Company has a low-risk business model and out-licenses its proprietary 
technologies to biopharmaceutical companies that have strong manufacturing and 
marketing capabilities. Lipoxen currently has commercial agreements with some of 
the world's leading biotechnology and pharmaceutical companies including Baxter, 
Schering-Plough, Sanofi-Aventis, the Serum Institute of India Limited, 
Genentech, Amgen and Genzyme. Furthermore, Baxter led the GBP2.9 million 
fundraising that the Company announced in May 2009, with a US$1 million 
investment. 
 
 
Lipoxen, which was founded in 1997, now trades on the AIM Market of the London 
Stock Exchange under the ticker symbol LPX. More information can be found at the 
Company's website: www.lipoxen.com. 
 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 STRILFVRDVISFIA